MedTrace Logo

Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders

NCT03146130 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2018-08-06

No results posted yet for this study

Summary

Impulse control disorders encountered in Parkinson's disease (PD) are induced by dopaminergic medications and their frequency is estimated to be nearly 20%, mainly under dopaminergic agonists (AD).

Conditions

  • Impulse Control Disorder
  • Parkinson

Interventions

BIOLOGICAL

Variation of behaviors of Parkinson's disease

Variation of hyper dopaminergic behaviors of Parkinson's disease

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Principal Investigators

  • Melissa TIR, Dr · CHU AMIENS-PICARDIE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-05
Primary Completion
2019-12-20
Completion
2019-12-20

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03146130 on ClinicalTrials.gov